Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
2019; Springer Nature; Volume: 120; Issue: 4 Linguagem: Inglês
10.1038/s41416-019-0377-x
ISSN1532-1827
AutoresT.R. Jeffry Evans, Emma Dean, L Rhoda Molife, Juanita Lopez, Malcolm Ranson, Fatima El-Khouly, Ishtiaq Husain Zubairi, Claudio Savulsky, Larisa Reyderman, Yan Jia, Lorna Sweeting, Alastair Greystoke, Jorge Barriuso, Rebecca Kristeleit,
Tópico(s)Nanoparticle-Based Drug Delivery
ResumoThis phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours.
Referência(s)